Literature DB >> 26705302

Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination.

Yi-Jiu Ren1, Yun-Lang She1, Chen-Yang Dai1, Ge-Ning Jiang1, Ke Fei1, Chang Chen2.   

Abstract

OBJECTIVES: Although non-small-cell lung cancer (NSCLC) with malignant pleural nodules is generally contraindicated for surgery, there is no consensus concerning on-site operative decisions for unexpected, intraoperatively encountered malignant pleural disseminations. The rationale underlying the primary tumour removal and other aggressive interventions remains controversial.
METHODS: All surgical NSCLC cases (9576) of Shanghai Pulmonary Hospital between January 2005 and December 2013 were reviewed. Among them, 83 cases (0.9%) met the definition of 'unexpected' macroscopic malignant pleural nodules, despite routine preoperative evaluations for tumour metastasis. No pleural effusion was visualized in 52 cases during operations, and 31 had pleural effusion in minimal volume (<300 ml). Survivals were calculated with the Kaplan-Meier method and risk factors were evaluated by the log-rank test.
RESULTS: The overall 3- and 5-year survival rates were 36.1 and 16.8%, respectively. The median survival time (MST) after surgery was significantly longer in the group without pleural effusion (37 months) compared with the group with pleural effusion (22 months, P = 0.005). Twenty-one cases had only biopsy, whereas 62 cases had primary tumour resection. Primary tumour resection had significantly better outcome compared with biopsy (MST: respectively, 35 vs 17 months, 3-year survival rate 45.8 vs 11.8%, P = 0.001). No baseline differences emerged in characteristics between biopsy and primary tumour resection groups including targeted therapy. Multivariate analysis showed that primary tumour resection (HR: 3.678, P = 0.014), no pleural effusion (HR: 3.409, P = 0.001) and adenocarcinoma (HR: 5.481, P = 0.002) were favourable prognostic factors in patients with malignant pleural nodules.
CONCLUSIONS: Patients with malignant pleural nodules but without pleural effusion had better survival compared with those with effusions. Primary tumour resection had survival benefits for patients with unexpected intraoperatively proven malignant pleural nodules.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Lung cancer; Malignant pleural dissemination; Prognosis; Surgery

Mesh:

Year:  2015        PMID: 26705302      PMCID: PMC4986565          DOI: 10.1093/icvts/ivv353

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  18 in total

1.  Integrated PET/CT and the dry pleural dissemination of peripheral adenocarcinoma of the lung: diagnostic implications.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Joon Young Choi; Young Mog Shim; Myung Jin Chung; O Jung Kwon; Eun Jeong Lee
Journal:  J Comput Assist Tomogr       Date:  2006 Jan-Feb       Impact factor: 1.826

2.  Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis?

Authors:  Noriyoshi Sawabata; Akihide Matsumura; Akira Motohiro; Yoshihiko Osaka; Keiichiro Gennga; Shimao Fukai; Takashi Mori
Journal:  Ann Thorac Surg       Date:  2002-02       Impact factor: 4.330

3.  Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications.

Authors:  Yi Kyung Kim; Ho Yun Lee; Kyung Soo Lee; Joungho Han; Myung-Ju Ahn; Keunchil Park; Young Mog Shim; Jhingook Kim
Journal:  Radiology       Date:  2011-06-03       Impact factor: 11.105

4.  Early experience with videothoracoscopic hydrodissection pleurectomy in the treatment of malignant pleural effusion.

Authors:  J C Harvey; C B Erdman; E J Beattie
Journal:  J Surg Oncol       Date:  1995-08       Impact factor: 3.454

5.  Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004.

Authors:  Tomohiko Iida; Mitsutoshi Shiba; Ichiro Yoshino; Etsuo Miyaoka; Hisao Asamura; Hiroshi Date; Meinoshin Okumura; Hirohito Tada; Yoichi Nakanishi; Hirotoshi Dosaka-Akita; Hideo Kobayashi; Kazuhisa Takahashi; Masayoshi Inoue; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

6.  Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy.

Authors:  Yasuhiko Ohta; Yosuke Shimizu; Isao Matsumoto; Masaya Tamura; Makoto Oda; Go Watanabe
Journal:  J Surg Oncol       Date:  2005-09-15       Impact factor: 3.454

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Early and late mortality after pleurodesis for malignant pleural effusion.

Authors:  Alain Bernard; Régis Bernard de Dompsure; Olivier Hagry; Jean Pierre Favre
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

9.  Prognostic value of pleural effusion in patients with non-small cell lung cancer.

Authors:  S Sugiura; Y Ando; H Minami; M Ando; S Sakai; K Shimokata
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

10.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

Authors:  K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  14 in total

1.  We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked.

Authors:  Yasuhiro Chikaishi; Ayako Hirai; Naoko Imanishi; Yoshinobu Ichiki; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis.

Authors:  Yuyang Xu; Nan Chen; Zihuai Wang; Yingyi Zhang; Jiandong Mei; Chengwu Liu; Lunxu Liu
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  The Prognostic Impact of Lymph Node Dissection on Primary Tumor Resection for Stage IV Non-Small Cell Lung Cancer: A Population-Based Study.

Authors:  Yudong Zhang; Yichi Zhang; Xinxin Cheng; Keyao Dai; Bo Xu; Shujun Liang; Minsheng Chen; Honglang Zhang; Zhenguang Chen
Journal:  Front Oncol       Date:  2022-05-05       Impact factor: 5.738

4.  Predictive factors related to pleural dissemination in non-small cell lung cancer.

Authors:  Nozomu Motono; Shun Iwai; Iijima Yoshihito; Katsuo Usuda; Sohsuke Yamada; Hidetaka Uramoto
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

5.  Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer.

Authors:  Yasuhiro Chikaishi; Shinji Shinohara; Taiji Kuwata; Masaru Takenaka; Soichi Oka; Ayako Hirai; Kazue Yoneda; Kouji Kuroda; Naoko Imanishi; Yoshinobu Ichiki; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

6.  The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected.

Authors:  Yijiu Ren; Chenyang Dai; Jianfei Shen; Yang Liu; Dong Xie; Hui Zheng; Jiaxi He; Wenhua Liang; Gening Jiang; Ke Fei; Ping Yang; Jianxing He; Chang Chen
Journal:  Oncotarget       Date:  2016-05-03

7.  Primary tumor resection of non-small cell lung cancer patients with ipsilateral pleural dissemination (M1a) in the era of targeted therapy.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Fan Yang
Journal:  Thorac Cancer       Date:  2020-09-18       Impact factor: 3.500

8.  Surgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination.

Authors:  Liwen Fan; Haitang Yang; Ke Han; Yang Zhao; Wen Gao; Ralph A Schmid; Feng Yao; Heng Zhao
Journal:  Front Surg       Date:  2021-06-23

Review 9.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06

10.  [Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma].

Authors:  Ying Chen; Wei Li; Wenfang Tang; Xuening Yang; Wenzhao Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.